---
title: "Varegacestat (AL102) in Desmoid tumors: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Humanistic burden and health-related quality of life. Topics: GODDESS development: concept elicitation and cognitive interviews; Disease impacts reported in GODDESS concept elicitation interviews; GODDESS psychometric properties and meaningful change thresholds in the DeFi trial; Desmoid Tumor Research Foundation natural history study, 2017 to 2023; 12 further topics. 16 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### GODDESS development: concept elicitation and cognitive interviews

> “CE interviews with desmoid patients (n = 31) helped to identify salient concepts and led to a draft scale that included symptom and impact scales. Cognitive interviews were completed with additional patients (n = 15) across 3 phases. Patient input was used to refine instructions, revise and/or remove items, and modify the response scale. This resulted in an 11-item symptom scale and a 17-item impact scale.”
> “This is the first disease-specific PRO instrument developed for desmoid tumors.”
> “Thirty-one patients (mean age, 44 years; standard deviation, 13 years; 77% female) completed the CE phase, and the demographics are described in Table 1. The majority of the patients had at least a college degree (71%) and were symptomatic (84%).”
> “A total of 33 unique symptoms were identified (Table 2).”

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

<a id="topic-2.2.1.8.1-2"></a>

### Disease impacts reported in GODDESS concept elicitation interviews

| Impact | Frequency of mentions (n = 31) | Median disturbance rating (0 to 10) |
| --- | --- | --- |
| Fear | “26” | “6.50” |
| Difficulty sleeping | “24” | “7.50” |
| Anxiety | “22” | “6.75” |
| Inability to do daily activities | “20” | “6.75” |
| Depression | “20” | “8.00” |
| Isolation | “17” | “7.00” |
| Financial difficulties | “16” | “8.00” |
| Hopelessness | “14” | “8.50” |
| Inability to do work | “14” | “6.75” |

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

<a id="topic-2.2.1.8.1-3"></a>

### GODDESS psychometric properties and meaningful change thresholds in the DeFi trial

> “DeFi participants (N = 142) had a median age of 34 years (range: 18–76) and were mostly female (64.8%), with extra-abdominal (76.8%) or intra-abdominal tumors (23.2%). The GODDESS© symptom/impact scales showed internal consistency at baseline, cycles 4 and 7 (Cronbach’s α > 0.70) and test–retest reliability (intra-class correlation coefficient > 0.85).”
> “For the total symptom score, a 1.30-point decrease was estimated as the within-person MCT and a 1.00-point decrease as the between-group MCT. For the physical functioning impact score, estimated within- and between-group MCTs were 0.60-point and 0.50-point decreases, respectively.”

Source: [Gounder et al. (2023c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10474203/)

<a id="topic-2.2.1.8.1-4"></a>

### Desmoid Tumor Research Foundation natural history study, 2017 to 2023

> “Surveys were completed by 399 participants between September 2017 and August 2023. The median age of participants was 38 years; most were female (72%, 288/399), White (84%, 334/399), or resided in North America (86%, 345/399).”
> “Participants with the presence of DT at survey completion reported significantly worse scores for pain, extra-abdominal symptoms, fatigue, physical functioning, and sleep in comparison to those without the current presence of a DT (P < 0.05).”
> “The overall mean Total Symptom Score for all participants was 4.1.”
> “The symptoms and impact of DT in a joint/extremity were reported to be significantly worse for the DTSS Total Symptom Score, DTSS Pain domain, and the DTIS Physical Functioning domain compared with other DT locations (all P < 0.05; Fig. 7a-c).”
> “Conversely, regardless of the current presence of DT, participants reported similar mean scores (P > 0.05) for the DTIS Emotional Impact domain (4.4 with current DT vs. 3.9 without current DT) and all Emotional Impact domain item scores, including Fear of Desmoid Tumor Growth/Recurrence (5.8 vs. 5.2), Anger (3.4 vs. 3.1), Anxiety (4.5 vs. 4.0), and Frustration (4.8 vs. 4.0), except Hopelessness (3.7 vs. 2.7; P = 0.007; data not shown).”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.8.1-5"></a>

### Physical symptom burden clusters in the United Kingdom and the Netherlands

> “Desmoid‐type fibromatosis patients from the United Kingdom and the Netherlands received cross‐sectional questionnaires on HRQoL (EORTC QLQ‐C30), DTF‐specific HRQoL (DTF‐QoL) and healthcare utilisation.”
> “Among 235 DTF patients, four symptom burden clusters were identified, with low symptom burden (24%), intermediate symptom burden‐low pain (20%), intermediate symptom burden‐high pain (25%) and high symptom burden (31%). DTF patients with high symptom burden had clinically relevant lower HRQoL scores compared to patients with low and intermediate symptom burden (p < 0.001)”

Source: [Schut et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10315709/)

<a id="topic-2.2.1.8.1-6"></a>

### DTF-QoL development in the United Kingdom and the Netherlands

> “The aim of this study was to pre-test the psychometric properties of the DTF-QoL by administering it together with the EORTC Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) to 236 DTF patients from the United Kingdom and the Netherlands.”
> “Ninety-six items were selected, conceptualised into three symptom scales, eleven disease-impact scales and six single items, together forming the final DTF-QoL.”

Source: [Schut et al. (2022a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8833407/)

<a id="topic-2.2.1.8.1-7"></a>

### Characteristics associated with poorer disease-specific quality of life

> “A total of 235 DTF patients completed the questionnaires. Female patients, patients with more than two comorbidities, or patients who received treatment other than only active surveillance (AS) or surgery scored significantly worse on the subscales of both the EORTC QLQ-C30 and DTF-QoL.”

Source: [Schut et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9221474/)

<a id="topic-2.2.1.8.1-8"></a>

### Quality of life, anxiety, and depression compared with healthy controls

> “Two hundred four subjects (102 DTF patients and 102 healthy controls) were recruited. The median age of DTF patients at recruitment into the study was 31 years (IQR, 25-37 years).”
> “The mean global health status in DTF patients was 65.58 ± 22.64, significantly lower than healthy controls. Similarly, DTF patients scored low on all functional scales except cognitive functioning. The symptom scale showed a significantly higher symptom burden of fatigue, pain, insomnia, and financial difficulties. Anxiety and depression was observed in 39.22% and 50% of DTF patients respectively.”

Source: [Garg et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36350382/)

<a id="topic-2.2.1.8.1-9"></a>

### Focus groups and interviews at a United Kingdom sarcoma unit

> “Twenty-seven DF patients were purposively sampled from The Royal Marsden Hospital. Two focus groups and 13 interviews (males 12, females 15; mean age at study 39.5 years) explored health-related quality of life issues and experiences of healthcare.”
> “Pain was the most debilitating symptom and dependency on painkillers was a significant concern. Functional limitation and restricted mobility frequently affected daily activities.”
> “low on all functioning scales (physical 74.4; role 55.8; social 52.8; cognitive 70.1; and emotional 56.9) and global QoL scale (56.9) of the EORTC QLQ-C30 and exceptionally high on the symptom scales pain (59.0), insomnia (56.9), fatigue (53.6) and financial difficulties (31.9).”

Source: [Husson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6373240/)

<a id="topic-2.2.1.8.1-10"></a>

### Literature review and focus groups on quality of life issues in sporadic desmoid-type fibromatosis

> “The search strategy identified thirteen articles reporting HRQL measures using a wide variety of cancer-specific HRQL tools, functional scores, symptom scales (e.g. NRS), and single-item outcomes (e.g. pain and functional impairment). No DTF-specific HRQL tool was found. Qualitative analysis of three focus groups (6 males, 9 females) showed that participants emphasised the negative impact of DTF and/or its treatment on several HRQL domains.”

Source: [Timbergen et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6244798/)

<a id="topic-2.2.1.8.1-11"></a>

### Anxiety and depression compared with malignant sarcoma

> “Despite its limited impact on survival, patients with DT may have anxiety and depression levels commensurate with those associated with malignant sarcomas.”
> “Interestingly, investigators found that anxiety and depression in patients with DT were significantly (P = 0.01) greater in patients with abdominal wall DT than in the sarcoma group, and among patients with DT outside of the abdominal wall, distress levels were equivalent to those of patients with malignant sarcomas.”

Source: [Kasper et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11166168/)

<a id="topic-2.2.1.8.1-12"></a>

### Pain at diagnosis in the ALTITUDES cohort

> “Overall, 382 patients were included in the current study (median age: 40.2 years; 117 men). The prevalence of pain was 36%, without significant difference according to first-line treatment (P = .18).”
> “Pain at baseline was significantly associated with poor quality of life (P < .001), depression (P = .02), lower performance status (P = .03) and functional impairment (P = .001)”

Source: [Penel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36883417/)

<a id="topic-2.2.1.8.1-13"></a>

### Pain burden survey by the French patient advocacy group SOS Desmoid

> “The pain occurrence was approximately 63%. In one-third of the cases, the pain was permanent. This pain led to severe social and economic consequences.”

Source: [Rigaux et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25747890/)

<a id="topic-2.2.1.8.1-14"></a>

### Pain and its consequences: systematic literature review

> “Patients with DT experience a high symptom burden: up to 63% of patients experience chronic pain, which leads to sleep disturbance (73% of cases), irritability (46% of cases), and anxiety/depression (15% of cases).”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

<a id="topic-2.2.1.8.1-15"></a>

### Patient and clinical expert testimony to NICE

> “The patient experts explained that it is difficult to live with desmoid tumours and that the most debilitating symptom is usually pain.”
> “The clinical experts added that pain is a major issue with sporadic desmoid tumours, especially extra-abdominal tumours, but was less of an issue in FAP-associated desmoid tumours.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-2.2.1.8.1-16"></a>

### Health state utility values in the NICE appraisal of nirogacestat

> “Although the De‑Fi trial did not collect EQ-5D data, it did collect quality-of-life data using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30.”
> “The utility values in the company base case were instead informed by published utility values from people with soft-tissue sarcoma (Shingler et al. 2013).”
> “The EAG stated that the utility value for progressed disease in the company base case was implausibly low for people with desmoid tumours (0.263).”
> “But, because this data was not provided, the EAG preferred to use utility values based on EQ-5D data from a clinical trial of people with soft-tissue sarcoma (Reichardt et al. 2012). This resulted in a utility value of 0.560 for progressed disease.”
> “The company acknowledged that the true utility value of progressed disease was likely to be between the company (0.263) and the EAG (0.560) base cases.”
> “At the second committee meeting, the company presented the EORTC QLQ-C30 quality-of-life data from De‑Fi, mapped to EQ-5D using the method from Young et al. (2015). These utilities are considered confidential by the company and so cannot be reported here.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
